J
James N. Ingle
Researcher at Mayo Clinic
Publications - 403
Citations - 52917
James N. Ingle is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 82, co-authored 387 publications receiving 47883 citations. Previous affiliations of James N. Ingle include McMaster University & University of Rochester.
Papers
More filters
Journal ArticleDOI
Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R
Yapeng Li,Xueying Zheng,Dongsheng Tu,James N. Ingle,Paul E. Goss,Wendy R. Parulekar,Guoyou Qin +6 more
TL;DR: In this paper, the authors developed a method to identify important prognostic factors associated with distant recurrence and developed a nomogram for predicting 5-year likelihood of recurrence, which was internally validated using bootstrap resampling method.
Journal ArticleDOI
Introduction to session on undue and disproportionate influences
James N. Ingle,William R. Miller +1 more
TL;DR: Th e session on undue and disproportionate inflences included three presentations that considered areas of profound importance for investigators involved with breast cancer research, peer review and the topic of statistical signifi cance.
Journal ArticleDOI
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
James N. Ingle,Krishna R. Kalari,Yukihide Momozawa,Michiaki Kubo,Yoichi Furukawa,Lois E. Shepherd,Matthew J. Ellis,Paul E. Goss,Poulami Barman,Erin E. Carlson,Jason P. Sinnwell,Xiaojia Tang,Matthew P. Goetz,Bingshu E. Chen,Junmei Cairns,Richard M. Weinshilboum,Liewei Wang +16 more
TL;DR: It was unable to identify common or rare variant regions that added value to the findings from the previous GWAS, and two haplotypes that were significant after adjusting for the top GWAS SNP were considered to be of marginal value.
Journal ArticleDOI
In reply [2]
Matthew P. Goetz,James M. Rae,Stephanie L. Safgren,Matthew M. Ames,Daniel W. Visscher,Carol Reynolds,Fergus J. Couch,Wilma L. Lingle,David A. Flockhart,Zeruesenay Desta,Edith A. Perez,James N. Ingle +11 more
Journal ArticleDOI
Abstract P4-02-09: Evaluation of the Automated Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC-005 Prospective Trial
Kala Visvanathan,Leslie Cope,Mary Jo Fackler,Michael Considine,Lisa A. Carey,Andres Forero-Torres,James N. Ingle,Nan Lin,Rita Nanda,Anna Maria Storniolo,Suzana Tulac,Natalie C. Wu,Sudhakar S. Marla,Neesha Venkatesan,Antonio C. Wolff,Saraswati Sukumar +15 more
TL;DR: Visvanathan et al. as mentioned in this paper used liquid biopsy-breast cancer methylation (LBx-BCM) to predict disease progression as early as 3 months after initiating a new treatment.